Nonmedication Devices in Development for the Treatment of Alzheimer's Disease

被引:0
|
作者
Sleem, Tamara [1 ]
Decourt, Boris [2 ]
Sabbagh, Marwan N. [1 ]
机构
[1] Barrow Neurol Inst, St Josephs Hosp & Med Ctr, Dept Neurol, Phoenix, AZ USA
[2] Texas Tech Univ Hlth Sci Ctr, Sch Med, Dept Pharmacol & Neurosci, Lubbock, TX USA
基金
美国国家卫生研究院;
关键词
Alzheimer's disease; clinical trials; devices; treatment; DEEP BRAIN-STIMULATION; TRANSCRANIAL MAGNETIC STIMULATION; VAGUS NERVE-STIMULATION; COGNITIVE FUNCTION; SYNAPTIC PLASTICITY; CORTEX EXCITABILITY; DOUBLE-BLIND; PHOTOBIOMODULATION; CONNECTIVITY; DEMENTIA;
D O I
10.3233/ADR-230115
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Huge investments continue to be made in treatment for Alzheimer's disease (AD), with more than one hundred drugs currently in development. Pharmacological approaches and drug development, particularly those targeting amyloid-beta, have dominated the therapeutic landscape. At the same time, there is also a growing interest in devices for treating AD. This review aimed to identify and describe devices under development for AD treatment. In this review, we queried the devices that are in development for the treatment of AD. PubMed was searched through the end of 2021 using the terms "device," "therapeutics," and "Alzheimer's" for articles that report on devices to treat AD. Ten devices with 31 references were identified as actively being developed for the treatment of AD. Many of these devices are far along in development. Device-based therapies are often overlooked when evaluating treatment approaches to AD. However, many devices for treating AD are in development and some show promising results.
引用
收藏
页码:241 / 255
页数:15
相关论文
共 50 条
  • [31] Masitinib for the treatment of Alzheimer's disease
    Ettecho, Miren
    Cano, Amanda
    Sanchez-Lopez, Elena
    Verdaguer, Ester
    Folch, Jaume
    Auladell, Carme
    Camins, Antoni
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2021, 11 (04) : 263 - 276
  • [32] Treatment Options for Alzheimer's Disease
    von Arnim, C.
    ZEITSCHRIFT FUR GERONTOLOGIE UND GERIATRIE, 2015, 48 : 33 - 33
  • [33] Advances in Alzheimer's disease treatment
    Nourhashemi, F.
    REVUE DE MEDECINE INTERNE, 2006, 27 (08): : 585 - 587
  • [34] Pharmacological treatment of Alzheimer's disease
    Bianchetti, A
    Ranieri, P
    Margiotta, A
    Trabucchi, M
    AGING CLINICAL AND EXPERIMENTAL RESEARCH, 2006, 18 (02) : 158 - 162
  • [35] Alzheimer's disease: Diagnosis and treatment
    Weiner, MF
    HARVARD REVIEW OF PSYCHIATRY, 1997, 4 (06) : 306 - 316
  • [36] Lecanemab in the treatment of Alzheimer’s disease
    Peters O.
    Nitschmann S.
    Die Innere Medizin, 2023, 64 (4) : 406 - 408
  • [37] Advances in the treatment of Alzheimer's disease
    Sloane, PD
    AMERICAN FAMILY PHYSICIAN, 1998, 58 (07) : 1577 - 1586
  • [38] Drug treatment for Alzheimer's disease
    Freyne, A
    Cooney, C
    IRISH MEDICAL JOURNAL, 1999, 92 (07) : 424 - 425
  • [39] Pioglitazone for the treatment of Alzheimer's disease
    Galimberti, Daniela
    Scarpini, Elio
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2017, 26 (01) : 97 - 101
  • [40] Rivastigmine in the treatment of Alzheimer's disease
    Deleu, D
    EUROPEAN NEUROLOGY, 2001, 46 (02) : 111 - 111